预约演示
更新于：2026-06-17
Ferrous sulfate
硫酸亚铁
更新于：2026-06-17
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1964-09-09), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式FeH16O11S |
InChIKeyZOUCGOUCHDLIRO-UHFFFAOYSA-N |
CAS号7782-63-0 |
关联
89
项与 硫酸亚铁 相关的临床试验CTIS2025-522498-12-00
A low-intervention randomised, double-blind, placebo-controlled pilot trial evaluating the feasibility, tolerability and adherence of alternate-day oral Duroferon (ferrous sulphate) in adolescent girls with iron deficiency, and the diagnostic performance of the IRON-5 screening tool (IRONGIRLS-PILOT).
NCT07605676
Effect of Transcutaneous Electrical Acupoint Stimulation Versus Resistance Exercise on Hemoglobin Level in Women With Iron Deficiency Anemia
NCT07081152
Long-term Iron Absorption and Losses in Young South African Women Living Without and With Overweight and Obesity
100 项与 硫酸亚铁 相关的临床结果
登录后查看更多信息
100 项与 硫酸亚铁 相关的转化医学
登录后查看更多信息
100 项与 硫酸亚铁 相关的专利（医药）
登录后查看更多信息
5,295
项与 硫酸亚铁 相关的文献（医药）2026-12-31Journal of Maternal-Fetal & Neonatal Medicine
Response of reticulocyte and red blood cell indices to single-dose intravenous iron in pregnant women with moderate iron deficiency anemia: secondary analysis of the RAPIDIRON trial
Article
作者: S., Yogeshkumar ; Somannavar, Manjunath S. ; Ramadurg, Umesh ; Sharma, Dharmesh Kumar ; Sangavi, Radha ; Derman, Richard J. ; Mehta, Seema ; Bellad, Mrutyunjaya B. ; Boelig, Rupsa C. ; Aghai, Zubair H. ; Leiby, Benjamin E. ; Charantimath, Umesh ; Patil, Praveen ; Mehta, Sudhir ; Mallapur, Ashalata ; Georgieff, Michael K. ; Akshaykirthan, J. P.
BACKGROUND:
Iron deficiency anemia in pregnancy is a significant health concern. Reticulocyte hemoglobin equivalent (Ret-He) and immature reticulocyte fraction (IRF) are emerging as early markers, yet their response to different iron therapies in pregnancy is underexplored.
OBJECTIVE:
To determine whether intravenous single-dose iron administration produces a more favorable effect on reticulocyte indices than oral iron therapy in anemic pregnant women.
METHODS:
This is a secondary analysis of the RAPIDIRON Trial, a multicenter, three-arm randomized controlled trial comparing ferric carboxymaltose (FCM), ferric derisomaltose (FDM) and standard oral ferrous sulfate. Reticulocyte hemoglobin equivalent (Ret-He), Immature Reticulocyte Fraction (IRF) and other red blood cell indices including Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Hemoglobin Concentration (MCHC) were measured at baseline (12-16 weeks), mid-gestation (26-30 weeks) and 42 days postpartum. Cord blood indices were assessed at delivery.
RESULTS:
By 26-30 weeks of gestation, iron deficient anemic women receiving IV iron demonstrated significant improvements in all red cell indices when compared to those receiving oral iron. Specifically, MCV increased by 2.87 fL (95% CI, 2.41-3.33) in the IV FDM group and 3.02 fL (95% CI, 2.54-3.49) in the IV FCM group compared to oral iron. Similarly Ret-He levels were also significantly increased in IV FDM and FCM compared to oral iron (1.32 (1.02, 1.63) and 1.31 (1.01, 1.62) respectively. By 42 days postpartum, intergroup differences in Ret-He, IRF and other parameters were no longer statistically significant, indicating that hematologic parameters had converged across treatment arms, reflecting restoration of iron homeostasis and stabilization of erythropoiesis in all groups.
CONCLUSION:
Intravenous iron therapy produces a more rapid and pronounced improvement in maternal red cell and reticulocyte indices than oral iron in moderately anemic pregnant women. Ret-He and IRF are emerging as early and sensitive biomarkers of iron availability and erythropoietic activity, with potential clinical utility for early detection of treatment response and optimization of iron therapy in pregnancy.
2026-09-01BIORESOURCE TECHNOLOGY
Superphosphate-driven low-pH regime reduces greenhouse gas emissions during manure composting
Article
作者: Wang, Yiming ; Wu, Pan ; Peng, Shuang ; Zhou, Beibei ; Hua, Qingqing ; Li, Huijie ; Yang, Yuchen ; Lin, Xiangui
Additives are widely used to mitigate greenhouse gas (GHG) emissions during manure composting, but whether additive combinations improve mitigation remains unclear. Here, we compared zeolite, ferrous sulfate, superphosphate, and their combinations in cattle manure composting. Superphosphate alone showed the strongest overall mitigation, reducing cumulative CH4 and N2O emissions by 87% and 38%, respectively, relative to the control. The best-performing combined treatment (FL) reduced cumulative CH4 and N2O emissions by 52% and 48%, respectively, indicating that FL performed better for N2O, whereas superphosphate alone achieved much stronger CH4 suppression and the best overall GHG mitigation. This effect was associated with a relatively lower-pH regime, higher NH4+-N retention, lower NO3- accumulation, and clear shifts in bacterial, archaeal, and functional gene profiles. Stage-specific multivariate analyses further showed that pH was strongly associated with late-stage functional reorganization, while treatment identity retained an independent effect after accounting for measured environmental variables. Overall, effective compost mitigation depended more on establishing a favorable physicochemical regime than on increasing additive complexity, and superphosphate treatment represented the most effective low-emission strategy in this system.
2026-07-01FOOD RESEARCH INTERNATIONAL
The binding mechanism of an iron-chelating peptide from duck plasma and insights into its absorption-enhancing effect in Caco-2 cells
Article
作者: Yang, Jing ; Ma, Jingjing ; Wang, Daoying ; Zhou, Ying ; Peng, Jiulan ; Cheng, Mei ; Zou, Ye ; Li, Zhiyu ; Yang, Biao ; Guo, Hanyu ; Xu, Weimin ; Luo, Cancan
This study aimed to elucidate the Fe2+ chelation mechanism of a duck plasma-derived peptide (RCLQ) and its iron bioavailability-enhancing potential, exploring a high-value strategy for duck blood by-product utilization. The RCLQ-Fe complex was prepared and characterized. Structural characterization, molecular docking and molecular dynamics simulation were employed to identify the specific chelation sites and binding mechanism. Stability under varying pH, temperature, and simulated gastrointestinal digestion was assessed. A Caco-2 monolayer model evaluated iron absorption efficacy via cellular ferritin levels and key iron metabolism-related gene/protein expression. Molecular simulations and spectral data revealed Fe2+ primarily binds to the amide oxygen of Leu and Gln within RCLQ. The RCLQ-Fe chelate demonstrates remarkable stability, outperforming conventional ferrous sulfate. In Caco-2 cells, ferritin levels in RCLQ-Fe-treated groups exceeded those in ferrous sulfate groups; the high-concentration RCLQ-Fe group showed 6.16-fold greater iron transport than controls at 120 min, via upregulating Dmt1, IRP1, Dcytb and Epn1. This study elucidated the Fe2+ binding mechanism of RCLQ and iron absorption-enhancing pathways of RCLQ-Fe in Caco-2 cells. It provides a theoretical basis for RCLQ-Fe as a promising high-efficiency iron fortifier and a novel strategy for high-value utilization of duck blood by-products.
100 项与 硫酸亚铁 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 缺铁性贫血 | 日本 | 1964-09-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 20 | Placebo+Ferrous Sulfate (Once Daily Dosing) | 糧蓋襯衊網簾鹹範餘繭(夢範觸廠願顧顧願鬱餘) = 築齋鏇餘壓襯網鹹範窪 襯鏇艱膚壓築獵簾廠襯 (構襯餘襯鏇願夢繭襯簾, 廠鑰蓋積獵鏇簾觸鏇醖 ~ 顧鹹窪願壓網簾膚繭窪) 更多 | - | 2024-09-19 | ||
(Twice Daily Dosing) | 糧蓋襯衊網簾鹹範餘繭(夢範觸廠願顧顧願鬱餘) = 製簾艱醖衊憲製襯窪製 襯鏇艱膚壓築獵簾廠襯 (構襯餘襯鏇願夢繭襯簾, 憲鹹簾範鏇齋蓋窪壓願 ~ 積築願廠築鹹襯壓淵淵) 更多 | ||||||
临床4期 | 14 | (Daily Iron Supplementation) | 鏇鑰壓鹽築憲鬱糧齋網(襯衊餘壓鏇壓獵齋衊壓) = 艱艱憲鬱鹽範膚顧壓淵 壓齋襯築膚遞襯積範壓 (醖夢鬱觸遞積鑰繭獵憲, 鑰繭鹽艱簾顧膚餘範網 ~ 淵選夢築遞窪簾築膚齋) 更多 | - | 2024-06-24 | ||
(Alternate Day Iron Supplementation) | 鏇鑰壓鹽築憲鬱糧齋網(襯衊餘壓鏇壓獵齋衊壓) = 憲觸鏇鹹網顧蓋獵網構 壓齋襯築膚遞襯積範壓 (醖夢鬱觸遞積鑰繭獵憲, 齋鹹鬱遞繭選繭壓觸製 ~ 餘願壓繭鏇網願選蓋構) 更多 | ||||||
临床4期 | 6 | (Ferrous Sulfate Daily) | 艱襯襯築遞鬱糧鏇齋糧 = 獵壓顧範願憲鑰糧膚糧 顧鹹製壓糧憲憲齋醖簾 (衊餘糧顧顧衊憲鹽製壓, 膚襯選餘鬱積艱廠鹹夢 ~ 繭淵獵選鹹壓構憲遞糧) 更多 | - | 2024-05-22 | ||
(Ferrous Sulfate Twice Daily) | 鑰構顧繭網膚膚窪鏇蓋 = 鬱膚蓋願衊鬱壓鹹製網 鑰願鏇廠鏇壓願製獵鹽 (淵窪醖餘願製襯蓋遞窪, 鑰觸獵繭鬱鑰鹽範獵襯 ~ 膚廠範糧廠襯鑰膚網遞) 更多 | ||||||
临床4期 | - | 480 | 60 mg ferrous sulfate | 築鹹願襯鏇夢遞衊廠獵(鏇簾鬱憲壓夢築鏇壓簾) = 網繭願鏇築齋選製積鬱 憲艱淵餘願窪鹹鑰鬱範 (網襯構窪糧觸衊繭糧鹹 ) | - | 2023-06-02 | |
築鹹願襯鏇夢遞衊廠獵(鏇簾鬱憲壓夢築鏇壓簾) = 壓艱繭艱積遞廠鹹廠鏇 憲艱淵餘願窪鹹鑰鬱範 (網襯構窪糧觸衊繭糧鹹 ) | |||||||
临床3期 | 1 | (Arm A: Oral Iron Therapy) | 淵鏇壓淵窪獵積壓觸獵 = 餘網襯製選艱膚衊餘選 獵襯鏇鏇選窪醖鹽糧範 (憲範築鑰積餘簾醖夢窪, 鹹遞餘壓顧糧鑰襯糧糧 ~ 顧艱顧製積廠範淵鏇積) 更多 | - | 2023-05-06 | ||
IRONCHILD+Ferrous Sulfate (Arm B: Oral Iron Therapy Plus IRONCHILD Web-based Intervention) | 淵鏇壓淵窪獵積壓觸獵 = 構壓鏇遞構膚選鏇積餘 獵襯鏇鏇選窪醖鹽糧範 (憲範築鑰積餘簾醖夢窪, 簾繭築廠鏇繭選築願壓 ~ 選醖願窪齋廠鬱積淵鏇) 更多 | ||||||
临床2/3期 | 54 | 範衊夢鑰繭網憲網齋廠(餘範夢願淵簾餘選鏇襯) = 醖獵餘夢遞蓋鹽艱夢鏇 襯選觸願鑰繭醖壓壓壓 (鏇襯膚餘廠齋鏇鏇觸蓋 ) | - | 2022-01-01 | |||
Placebo | 範衊夢鑰繭網憲網齋廠(餘範夢願淵簾餘選鏇襯) = 獵繭簾齋艱網遞糧顧築 襯選觸願鑰繭醖壓壓壓 (鏇襯膚餘廠齋鏇鏇觸蓋 ) | ||||||
临床4期 | 60 | 艱醖夢醖遞繭製艱窪鑰(獵膚襯積顧選憲蓋壓選) = 獵鹽壓襯衊構獵簾衊顧 餘餘遞願簾構膚構淵獵 (蓋窪衊廠簾襯鏇醖鹹繭 ) | - | 2021-02-04 | |||
临床4期 | 198 | (Injectafer) | 憲鏇積廠觸繭壓餘壓鑰 = 窪襯鏇獵構齋窪糧廠遞 鏇鹽觸顧鏇積蓋憲齋繭 (鏇繭鏇積遞衊鬱積醖鹽, 鏇鹹遞範構蓋網窪鬱鑰 ~ 鹹淵衊餘鬱膚廠鑰鹹鹹) 更多 | - | 2020-09-17 | ||
(Ferrous Sulfate Tablets) | 憲鏇積廠觸繭壓餘壓鑰 = 齋糧鏇繭衊鏇廠糧觸網 鏇鹽觸顧鏇積蓋憲齋繭 (鏇繭鏇積遞衊鬱積醖鹽, 築鹹構顧鹽製齋廠鹹壓 ~ 積構繭鑰壓襯鬱簾觸蓋) 更多 | ||||||
临床2期 | 200 | (Iron Group) | 構積遞鬱願願膚壓蓋糧(願構繭選觸製構膚繭齋) = 淵遞蓋繭築網鏇選顧廠 糧繭構襯構築顧糧夢鏇 (壓積齋選窪壓網衊醖醖, 0.5) 更多 | - | 2019-07-08 | ||
Placebo Oral Tablet (Placebo Group) | 構積遞鬱願願膚壓蓋糧(願構繭選觸製構膚繭齋) = 窪鬱顧餘鏇鏇積觸鑰鑰 糧繭構襯構築顧糧夢鏇 (壓積齋選窪壓網衊醖醖, 0.5) 更多 | ||||||
N/A | 246 | Ferric Carboxymaltose (FCM) | 鏇範糧構鏇觸蓋鹹積壓(鹽鹹壓餘憲繭襯繭醖醖) = 鹹遞遞壓選鬱獵壓壓衊 衊築廠鹹膚構鬱觸觸衊 (窪願夢鬱餘糧膚鹽衊淵 ) | - | 2018-10-01 | ||
Iron Polymaltose (IPM) | - |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用